DNB Asset Management AS Increases Stake in Bruker Corporation $BRKR

DNB Asset Management AS grew its holdings in Bruker Corporation (NASDAQ:BRKR) by 40.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,257 shares of the medical research company’s stock after acquiring an additional 41,289 shares during the period. DNB Asset Management AS owned 0.09% of Bruker worth $4,654,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sector Gamma AS grew its holdings in Bruker by 28.0% during the third quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock valued at $8,152,000 after purchasing an additional 54,939 shares during the period. M&G PLC lifted its position in shares of Bruker by 233.0% during the 3rd quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock valued at $35,079,000 after buying an additional 766,992 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Bruker by 52.5% during the 3rd quarter. New York State Common Retirement Fund now owns 370,797 shares of the medical research company’s stock valued at $12,047,000 after acquiring an additional 127,698 shares during the period. Jefferies Financial Group Inc. purchased a new stake in Bruker in the 2nd quarter worth approximately $2,361,000. Finally, Old West Investment Management LLC raised its stake in Bruker by 144.2% during the 3rd quarter. Old West Investment Management LLC now owns 573,462 shares of the medical research company’s stock worth $18,632,000 after acquiring an additional 338,618 shares during the period. Institutional investors own 79.52% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on BRKR. Barclays dropped their price target on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Wells Fargo & Company increased their price target on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. TD Cowen decreased their price target on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a report on Friday, February 13th. Guggenheim upped their price objective on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, UBS Group reiterated a “neutral” rating and set a $49.00 target price on shares of Bruker in a research report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Bruker presently has a consensus rating of “Hold” and an average target price of $50.38.

Bruker Stock Down 0.7%

NASDAQ BRKR opened at $39.81 on Tuesday. The stock has a 50 day moving average price of $45.46 and a 200-day moving average price of $40.94. Bruker Corporation has a one year low of $28.53 and a one year high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The company has a market capitalization of $6.05 billion, a P/E ratio of -265.40, a P/E/G ratio of 2.40 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. During the same period in the previous year, the company earned $0.76 EPS. Bruker’s revenue for the quarter was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a $0.05 dividend. The ex-dividend date is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is currently -133.33%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $6,319,395.60. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 27.30% of the stock is owned by insiders.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.